| 1. | Thromboembolic event rates differ according to various guideline treatment thresholds and methodological approaches.
|
| 2. | Administration of the latter is also associated with increased risk of venous thromboembolic complications.
|
| 3. | It can lead to either bleeding or thromboembolic complications, or is clinically without pathological findings.
|
| 4. | Its main use, therefore, is to exclude thromboembolic disease where the probability is low.
|
| 5. | Pulmonary thromboendarterectomy ( PTE ) is a surgical procedure that is used for chronic thromboembolic pulmonary hypertension.
|
| 6. | Studies have demonstrated an increased risk of recurrent venous thromboembolic events in patients with protein C deficiency.
|
| 7. | Cavitation is also suspected as a contributing factor in blood cell damage and increased risk of thromboembolic complications.
|
| 8. | From 1965 to 1967 Inman designed and directed studies on the role of oral contraceptives in thromboembolic disease.
|
| 9. | In chronic thromboembolic pulmonary hypertension patients, Ral GTPases have been observed to be highly active in their platelets.
|
| 10. | In the clinic, heparin is administered as an anticoagulant and is also the first line choice for thromboembolic diseases.
|
मोबाइल